Tag: IHL
Incannex commences animal trial to establish optimal dosage of IHL-216A in treating traumatic brain injuries
Cannabinoid development company Incannex Healthcare (ASX: IHL) has commenced a pre-clinical animal trial investigating the neuroprotective capabilities of its lead candidate IHL-216A.
The trial wil...
Incannex reports positive results from animal study into CBD-based drug for ARDS resulting from COVID-19
After reporting amiable progress concerning its sleep apnoea drug IHL-42X just last week, cannabinoid drug development company Incannex Healthcare (ASX: IHL) has published positive results from its an...
Incannex partners with The Alfred Hospital for clinical trial to study impact of cannabinoid drug on patients with obstructive sleep apn...
Clinical stage cannabinoid development company Incannex Healthcare (ASX: IHL) has partnered with The Alfred Hospital in Melbourne for a phase 2b dose finding crossover trial investigating the effect o...
Incannex Healthcare shifts from making an impression to setting sales records
Cannabinoid development company Incannex Healthcare (ASX: IHL) has published provisional performance figures for the past quarter, declaring a “record” three months with sales momentum expected to con...
Impression Healthcare to focus exclusively on cannabinoid sales and drug development
Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to focus its resources exclusively on cannabinoid sales an...
Impression Healthcare starts CBD drug trial to fight leading cause of COVID-19 deaths
Impression Healthcare (ASX: IHL) has begun the first clinical trial to assess the effectiveness of its cannabidiol (CBD) based drug IHL-675A against sepsis associated acute respiratory distress syndro...
Impression Healthcare recruits NRL star James Graham to boost commercial development of IHL-216A
Medical cannabis company Impression Healthcare (ASX: IHL) has unveiled a high profile acquisition in the form of professional rugby league footballer James Graham.
In a statement to the market this m...
Impression Healthcare to commence animal testing of CBD drug for COVID-19 related respiratory conditions
Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of animal pre-clinical testing of cannabinoid drug IHL-675A de...
Impression Healthcare targets 2024 commercialisation of cannabinoid treatment for traumatic brain injury
Medical cannabis company Impression Healthcare (ASX: IHL) has confirmed plans to bring its novel cannabinoid formula IHL-216A for patients with traumatic brain injury to the prescription market within...
Impression Healthcare develops CBD-based drug as potential treatment for coronavirus symptoms
Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for the treatment of coronavirus-induced respiratory distress ...
Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X
Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA approval pathway for cannabinoid IHL-42X from US-based Cama...
Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme
Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidiol (CBD) pressurised metered-dose inhalers (similar to an...
Impression drafts former AFL star Liam Picken to its advisory board
Australian medical cannabis company Impression Healthcare (ASX: IHL) has taken yet another assertive step towards completing its clinical research program into concussion and traumatic brain injury (T...
Impression Healthcare to launch medical cannabis trials for treatment of traumatic brain injury
Australian medical cannabis company Impression Healthcare (ASX: IHL) has finalised the design of a clinical program to assess novel cannabinoid formula IHL-216A on neurocognitive function after trauma...
Impression Healthcare expands cannabinoid oil sales program
Medical cannabis company Impression Healthcare (ASX: IHL) has expanded its cannabinoid oil sales program that runs side by side with its extensive base of clinical trial projects.
In a statement to...
Impression Healthcare prepares for obstructive sleep apnoea clinical trial
Medical cannabis company Impression Healthcare (ASX: IHL) is on course to begin a clinical trial using its IHL-42X drug candidate for the treatment of obstructive sleep apnoea.
The drug was recentl...
Impression Healthcare files patent for non-intrusive treatment of obstructive sleep apnoea
Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a patent application covering IH...
Impression Healthcare recruits Big Pharma executive to complete cannabinoid drug discovery goal
Medical cannabis company Impression Healthcare (ASX: IHL) has continued its top-tier recruitment drive with the addition of yet another pharmaceutical industry expert into its ranks.
Former Roche (...
Impression Healthcare files patent application for medicinal CBD drug to alleviate concussion injuries
Impression Healthcare (ASX: IHL) has opted to file a patent application for a neuroprotective agent that could potentially aid people that suffer concussions – a growing issue in contact sports such a...
Duo of renowned specialists join Impression Healthcare, Incannex CBD oils on route
Following a busy few months on the recruitment and brand licencing fronts, Impression Healthcare (ASX: IHL) has appointed an additional duo of leading medical experts to its Medical Advisory Board, ov...
Impression Healthcare appoints two globally renowned medical experts for cannabis medicines projects
Impression Healthcare (ASX: IHL) has bolstered its Medical Advisory Board by appointing two leading medical experts possessing extensive expertise within two key market niches currently being explored...
